Registrations open for AusBiotech 2013
26 April, 2013The biggest Australian biotechnology event for the year, the AusBiotech 2013 national conference, will be held from 29 October-1 November in Brisbane. Registrations are now open.
STA cleared to market C. difficile treatment
26 April, 2013 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has won approval to market fidaxomicin - the C. difficile treatment licensed from Optimer Pharmaceuticals - in Australia.
Phylogica granted EU Phylomer patent
25 April, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has received a European patent covering the use of Phylomer peptides from its libraries to treat ischemic conditions including stroke and ARDS.
Pharmaxis shares plunge on new Bronchitol setback
24 April, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has revealed a phase III trial of Bronchitol in bronchiectasis failed to meet its primary goal, sending its share price falling 45%.
Prima names new advisors for CVac programs
24 April, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has appointed oncology experts Dr Holbrook Kohrt and Dr Pamela Klein as clinical advisors for its cancer vaccine programs.
Alchemia lands discovery deal with AstraZeneca
23 April, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has entered a small molecule drug discovery collaboration with AstraZeneca based on the former’s VAST chemistry platform.
Bionomics initiates manufacturing of tumour drug
23 April, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has contracted Lonza to produce tumour drug candidate BNC101 ahead of clinical trials anticipated for 2014.
Registration deadline looming for R&D Tax Incentive
23 April, 2013The registration of research and development (R&D) activities, under the R&D Tax Incentive, closes next week for the 2011-12 year.
Swedish agencies to trial Bioniche E. coli vaccine
19 April, 2013 by Dylan Bushell-EmblingSwedish government agencies will incorporate Bioniche’s (ASX:BNC) E. coli O157 cattle vaccine in its research into limiting human infection by verotoxigenic E. coli.
Novogen’s largest shareholder leaves board
19 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) non-executive director Josiah Austin has resigned to avoid having to fly from the US to Australia for monthly board meetings.
Starpharma secures dendrimer patents
18 April, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has been granted three new US patents for its dendrimer drug delivery platform and will soon pick up a patent in China.
Pharma Patent Review releases draft report for comment
18 April, 2013The Draft Report of the Pharmaceutical Patent Review is now open for comment.
Mesoblast board gets a Rose
17 April, 2013Dr Eric Rose, the cardiovascular surgeon who performed the first successful paediatric heart transplant, has joined Mesoblast’s board of directors.
Delayed reaction
17 April, 2013 by Tim Dean2012 wasn’t the breakthrough year many were expecting for Australian biotechs, but 2013 could be.
Quarterly R&D tax credit payments one step closer
16 April, 2013The federal government has released the draft legislation, to provide the research and development (R&D) tax incentive through quarterly credits, for public comment.
